Baseline Characteristics of the Patients Part I

Slides:

Advertisements

Similar presentations

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Advertisements

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Philip J. Barter, et al. Circulation 2011;124:

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Clinical Trial Results. org RAAVE Luis M. Moura, MD; Sandra F. Ramos, MSc; José L. Zamorano, MD, PhD; Isabel M. Barros, MD; Luis F. Azevedo, MD; Francisco.

Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

Algorithms proposed by the Heart Valve Clinic International Database (HAVEC) group for disease staging and management in patients with aortic valve stenosis.

Oxford Niacin Trial.

FATS- Familial Atherosclerosis Treatment Study

TNT: Baseline and final LDL cholesterol levels

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Western Norway B-vitamin Intervention Trial

TNT Study: Baseline Characteristics of the Patients

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Jun M, et al. Lancet 2010 Epub May 10

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Nat. Rev. Cardiol. doi: /nrcardio

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Figure 2 A patient with aortic stenosis and mitral regurgitation

End point Fenoldopam, n (%) Dopamine, n (%) p

Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft.

Miralem Pasic et al. JCIN 2015;8:1-9

Patient characteristics in the entire study group

Potential mechanisms whereby statins may reduce the risk of stroke

Enrollment and Outcomes

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Baseline Characteristics by Tertiles of Homocysteine

Baseline Characteristics of the Subjects

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

A.V. Khera et al. N Engl J Med 2011;364:127-35

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Clinical Characteristics

Baseline Characteristics of the Subjects*

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Disposition of Patients in the Atherogenic Dyslipidemia Study

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Calcium on trial: Beyond a reasonable doubt?

Baseline Characteristics of the Patients – Part I

RECORD Study: Enrollment and Outcomes

Characteristics of included studies

Baseline Characteristics of the Patients - Part I

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

Baseline Characteristics of the Patients Part I S.Joanna Cowell et al N Engl J Med 2005;352:2389-97

Baseline Characteristics of the Patients Part II S.Joanna Cowell et al N Engl J Med 2005;352:2389-97

Progression in Aortic-Valve Stenosis and Serum LDL Cholesterol Concentrations in Patients Treated with Intensive Atorvastatin Therapy or Matched Placebo S.Joanna Cowell et al N Engl J Med 2005;352:2389-97

Progression from Baseline of Aortic-Valve Stenosis on Echocardiography and Computed Tomography S.Joanna Cowell et al N Engl J Med 2005;352:2389-97

Number of Patients Reaching Secondary End Points S.Joanna Cowell et al N Engl J Med 2005;352:2389-97

Subgroup Analyses of Disease Progression According to Aortic-Jet Velocity S.Joanna Cowell et al N Engl J Med 2005;352:2389-97